New drug cocktail aims to stop lung cancer return in Early-Stage patients

NCT ID NCT07485920

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining two drugs, tislelizumab and nintedanib, can help control limited-stage small cell lung cancer after standard chemoradiation. About 20 adults with good performance status will receive this consolidation therapy. The goal is to delay cancer progression and improve survival, while monitoring side effects like lung inflammation.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Qingdao Central Hospital Affiliated to Rehabilitation University

    Qingdao, Shandong, China

    Contact Email: •••••@•••••

  • Qingdao Municipal Hospital

    Qingdao, Shandong, China

    Contact Email: •••••@•••••

  • Weihai Municipal Hospital

    Weihai, Shandong, China

    Contact Email: •••••@•••••

  • Yantai Yuhuangding Hospital

    Yantai, Shandong, China

    Contact Email: •••••@•••••

  • Zibo Fourth People's Hospital

    Zibo, Shandong, China

    Contact Email: •••••@•••••